A phase 2 trial with ABI-009 (nab-sirolimus) as single-agent and combinations in recurrent high-grade glioma (rHGG) and in newly diagnosed glioblastoma (ndGBM)

Home A phase 2 trial with ABI-009 (nab-sirolimus) as single-agent and combinations in recurrent high-grade glioma (rHGG) and in newly diagnosed glioblastoma (ndGBM)

A phase 2 trial with ABI-009 (nab-sirolimus) as single-agent and combinations in recurrent high-grade glioma (rHGG) and in newly diagnosed glioblastoma (ndGBM)

/ Publications

Share the Post

About the Author

Related Posts

nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors
Aadi Reports Third Quarter 2021 Financial Results and Provides Business Update
Read More
Dave Lennon
Read More
Anupam Dalal, MD
Aadi Bioscience Receives Breakthrough Therapy Designation for ABI-009 in PEComa Indication
Read More
Andrew Kwon, PhD
A phase I/II multicenter study of ABI-009 (nab-sirolimus) combined with FOLFOX and bevacizumab as first-line (1L) therapy in patients (pts) with metastatic colorectal cancer (mCRC) with or without PTEN loss
Read More
Behzad Aghazadeh, PhD

Comments

Comments are closed.